Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab with Chemoradiation for Cervical Cancer
NCT01301612Phase 2Withdrawn
- Sponsor
- Eurofarma
- Start
- Jan 2011
- Primary completion
- Dec 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nimotuzumab in Cervical Cancer (CC), sponsored by Eurofarma. Planned start Jan 2011; status: withdrawn.
02
Drugs
nimotuzumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT01301612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01301612.